Repositioning Candidate Details
| Candidate ID: | R0645 |
| Source ID: | DB04917 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Renzapride |
| Synonyms: | Renzapride |
| Molecular Formula: | C16H22ClN3O2 |
| SMILES: | COC1=C(C=CC(N)=C1Cl)C(=O)NC1CCN2CCCC1C2 |
| Structure: |
|
| DrugBank Description: | Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK. |
| CAS Number: | 112727-80-7 |
| Molecular Weight: | 323.818 |
| DrugBank Indication: | For the treatment of constipation-predominant irritable bowel syndrome (IBS-C). |
| DrugBank Pharmacology: | Renzapride is a substituted benzamide which acts on the upper gastrointestinal tract. It has been shown to enhance stomach emptying in normal subjects; doses of 2 and 5 mg decreasing by 21 and 37% respectively the volume of gastric contents aspirated 80 min after a test meal. Renzapride was found to reduce the oro-caecal transit time as assessed by the lactulose/breath hydrogen method in a dose related manner from 0.2 to 5 mg; the later dose producing a 62% reduction. |
| DrugBank MoA: | Renzapride is a full serotonin 5-HT4 receptor agonist and partial serotonin 5-HT3 receptor antagonist. |
| Targets: | 5-hydroxytryptamine receptor 3A; 5-hydroxytryptamine receptor 4 |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|